4 completed, 1 terminated, 1 unknown, 1 withdrawn. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow Adjuvant: new trials by email Literature Review of Adjuvant trials Research Report on Adjuvant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab Pembrolizumab, Pembrolizumab and Olaparib, Pembrolizumab adjuvant - Cancer | Phase 2 | Withdrawn | Gustave Roussy, Cancer Campus, Grand Paris | 2025-01-01 | 2025-12-01 | |
| The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults SCTV01C, Adjuvant, Saline - COVID-19 | Phase 1 / Phase 2 | Completed | Sinocelltech Ltd. | 478 | 2021-12-01 | 2024-02-08 |
| Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection GEN-003, Matrix-M2, 0.9% normal saline - Genital Herpes, HSV-2 Infection | Phase 2 | Terminated | Genocea Biosciences, Inc. | 33 | 2017-05-24 | 2019-02-19 |
| Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL TVGV-1, GPI-0100, Placebo - Human Papillomavirus, High-Grade Squamous Intraepithelial Lesions | Phase 2 | Unknown | THEVAX Genetics Vaccine | 10 | 2015-11-01 | 2017-10-25 |
| Evaluating New Formulation of Therapeutic HSV-2 Vaccine Matrix-M2, GEN-003, Placebo - Genital Herpes Simplex Type 2 | Phase 2 | Completed | Genocea Biosciences, Inc. | 131 | 2015-11-01 | 2018-05-22 |
| Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg) - Genital Herpes Simplex Type 2 | Phase 2 | Completed | Genocea Biosciences, Inc. | 37 | 2015-01-01 | 2017-10-16 |
| Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg) - Genital Herpes Simplex Type 2 | Phase 2 | Completed | Genocea Biosciences, Inc. | 310 | 2014-07-01 | 2017-10-16 |
Herpes Simplex (4) · Herpes Genitalis (2) · COVID-19 (1) · Liposarcoma (1) · Neoplasms (1) · Sarcoma (1) · Squamous Intraepithelial Lesions (1) · Uterine Cervical Dysplasia (1)
Genocea Biosciences, Inc. (4) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Sinocelltech Ltd. (1) · THEVAX Genetics Vaccine (1)
United States (5) · China (1) · France (1)
Frank L Douglas, PhD, MD (1) · Yimin Cui, M.D. (1)